Docetaxel Injection, Solution
Product Images NDC 25021-245

13 FDA label images from Sagent Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 25021-245). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Doc07 0010 01)

Structural Formula (Doc07 0010 01)
Chemical structure of Docetaxel Anhydrous, the active ingredient in Docetaxel injection solution 20 mg/mL by Sagent Pharmaceuticals.*
FDA Label Image

Figure 1 (Doc07 0010 02)

Figure 1 (Doc07 0010 02)
A line graph displaying Disease-Free Survival (DFS) Probability (%) over time in months up to 72 months. The graph compares two groups labeled TAC and FAC, showing their DFS probabilities decreasing over time with TAC consistently above FAC.*
FDA Label Image

Figure 2 (Doc07 0010 03)

Figure 2 (Doc07 0010 03)
A Kaplan-Meier survival curve graph showing survival probability over time in months for two groups labeled TAC and FAC. The vertical axis represents survival probability percentage from 0 to 100%, and the horizontal axis represents survival time from 0 to 66 months. The chart displays survival trends of two different treatment groups without specific numeric data highlighted.*
FDA Label Image

Figure 3 (Doc07 0010 04)

Figure 3 (Doc07 0010 04)
A Kaplan-Meier survival curve chart showing cumulative probability versus survival time in months. Two curves are labeled T75 and BSC, with T75 having a higher survival probability over time compared to BSC. The chart includes an overall survival log-rank p-value of 0.010.*
FDA Label Image

Figure 4 (Doc07 0010 05)

Figure 4 (Doc07 0010 05)
A survival curve chart showing cumulative probability versus survival time in months. The graph compares two groups, labeled T75 and V/I, with survival probability decreasing over time up to 21 months. The chart includes a log-rank p-value of 0.13 for overall survival comparison.*
FDA Label Image

Figure 5 (Doc07 0010 06)

Figure 5 (Doc07 0010 06)
A Kaplan-Meier survival curve graph showing survival probability over time (in months) up to 30 months. Two treatment groups are compared: T75 q3w (solid line) and M q3w (dashed line), with survival probability on the vertical axis and time in months on the horizontal axis.*
FDA Label Image

Figure 6 (Doc07 0010 07)

Figure 6 (Doc07 0010 07)
A Kaplan-Meier survival curve chart depicting probability over time in months. Two curves are shown: one labeled TCF and the other CF, illustrating comparative survival probabilities up to 24 months.*
FDA Label Image

Figure 7 (Doc07 0010 08)

Figure 7 (Doc07 0010 08)
A survival probability Kaplan-Meier curve chart comparing two groups, TCF and CF, plotted over survival time in months (0 to 36). The vertical axis shows survival probability percentages from 0 to 100%, illustrating the probability of survival decreasing over time for both groups.*
FDA Label Image

Figure 8 (Doc07 0010 09)

Figure 8 (Doc07 0010 09)
A Kaplan-Meier survival curve graph depicting progression-free survival (PFS) probability over time in months. Two curves are shown: one solid line labeled TPF and one dashed line labeled PF, illustrating different patient groups or treatment protocols.*
FDA Label Image

Figure 9 (Doc07 0010 10)

Figure 9 (Doc07 0010 10)
A Kaplan-Meier survival curve chart showing survival probability over time in months. It compares two groups labeled TPF and PF, with survival probability on the y-axis and survival time (months) on the x-axis, demonstrating differences in survival trends between the groups.*
FDA Label Image

Figure 10 (Doc07 0010 11)

Figure 10 (Doc07 0010 11)
A Kaplan-Meier survival curve chart showing survival probability (%) over time (months) for two groups: TPF (n=255) and PF (n=246). The graph illustrates declining survival over time for both groups, with TPF showing better survival probability compared to PF. The number of patients at risk at various time points is listed below the x-axis.*
FDA Label Image

Package Label – Principal Display Panel – Vial Label (Doc07 0010 12)

Package Label – Principal Display Panel – Vial Label (Doc07 0010 12)
Label for Docetaxel Injection, USP 20 mg/mL, a 1 mL single-dose vial for intravenous infusion only. The label includes a warning that it is a cytotoxic agent and provides vial formulation details including 20 mg docetaxel in 50/50 vinyl alcohol and polysorbate 80 with citric acid. Manufactured by Sagent Pharmaceuticals in Schaumburg, IL, with product NDC 25021-245-01. The label instructs to protect from light and store between 2 and 25°C.*
FDA Label Image

Package Label – Principal Display Panel – Vial Label (Doc07 0010 13)

Package Label – Principal Display Panel – Vial Label (Doc07 0010 13)
Label for Docetaxel Injection, USP 80 mg per 4 mL (20 mg per mL) intravenous solution. The label includes a warning that the product is a cytotoxic agent and instructions that it is a single-dose vial for intravenous infusion only. It is manufactured for Sagent Pharmaceuticals in Schaumburg, IL. The vial contains 4 mL of solution and advises protection from light and storage between 2° and 25°C.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.